639 related articles for article (PubMed ID: 33870886)
1. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
Sønderskov KM; Dinesen PT; Østergaard SD
Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
[TBL] [Abstract][Full Text] [Related]
2. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
3. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study.
Bernardi FF; Mascolo A; Sarno M; Capoluongo N; Trama U; Ruggiero R; Sportiello L; Fusco GM; Bisogno M; Coscioni E; Iervolino A; Di Micco P; Capuano A; Perrella A
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896978
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
6. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
[TBL] [Abstract][Full Text] [Related]
7. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
Pottegård A; Lund LC; Karlstad Ø; Dahl J; Andersen M; Hallas J; Lidegaard Ø; Tapia G; Gulseth HL; Ruiz PL; Watle SV; Mikkelsen AP; Pedersen L; Sørensen HT; Thomsen RW; Hviid A
BMJ; 2021 May; 373():n1114. PubMed ID: 33952445
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
Rosero-Bixby L
JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
[TBL] [Abstract][Full Text] [Related]
9. The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis.
Jain V; Lorgelly P
Eur J Public Health; 2022 Aug; 32(4):648-654. PubMed ID: 35394507
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population.
Moradi Hasan-Abad A; Arbabi M; Gilasi H; Motedayyen H
Int J Immunopathol Pharmacol; 2024; 38():3946320241239202. PubMed ID: 38494849
[No Abstract] [Full Text] [Related]
11. People's Willingness to Vaccinate Against COVID-19 Despite Their Safety Concerns: Twitter Poll Analysis.
Eibensteiner F; Ritschl V; Nawaz FA; Fazel SS; Tsagkaris C; Kulnik ST; Crutzen R; Klager E; Völkl-Kernstock S; Schaden E; Kletecka-Pulker M; Willschke H; Atanasov AG
J Med Internet Res; 2021 Apr; 23(4):e28973. PubMed ID: 33872185
[TBL] [Abstract][Full Text] [Related]
12. DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination.
Casucci G; Acanfora D
Viruses; 2021 Jun; 13(6):. PubMed ID: 34205940
[TBL] [Abstract][Full Text] [Related]
13. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.
Leclerc S; Royal V; Lamarche C; Laurin LP
Am J Kidney Dis; 2021 Oct; 78(4):607-610. PubMed ID: 34242687
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.
Sessa M; Kragholm K; Hviid A; Andersen M
Expert Opin Drug Saf; 2021 Nov; 20(11):1451-1453. PubMed ID: 34264151
[No Abstract] [Full Text] [Related]
15. Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination.
Kreps S; Prasad S; Brownstein JS; Hswen Y; Garibaldi BT; Zhang B; Kriner DL
JAMA Netw Open; 2020 Oct; 3(10):e2025594. PubMed ID: 33079199
[TBL] [Abstract][Full Text] [Related]
16. Side effects after COVID-19 vaccinations among residents of Poland.
Andrzejczak-Grządko S; Czudy Z; Donderska M
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
[TBL] [Abstract][Full Text] [Related]
17. Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines.
Marcec R; Likic R
Postgrad Med J; 2022 Jul; 98(1161):544-550. PubMed ID: 34373343
[TBL] [Abstract][Full Text] [Related]
18. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
[TBL] [Abstract][Full Text] [Related]
19. A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran.
Soltani S; Matin BK; Gouya MM; Zahraei SM; Moradi G; Chehri O; Soofi M; Moradinazar M; Shadmani FK; Kalantari M; Khajeha H; Emamian MH; Najafi F
BMC Public Health; 2023 Jul; 23(1):1415. PubMed ID: 37488541
[TBL] [Abstract][Full Text] [Related]
20. A positive update on COVID-19 booster vaccine willingness among Danes.
Sønderskov KM; Vistisen HT; Dinesen PT; Østergaard SD
Dan Med J; 2022 Jan; 69(2):. PubMed ID: 35088699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
